Biomea Fusion, Inc.
Biomoda, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral, small molecule drugs to treat diabetes, obesity, and other metabolic diseases. The company was founded in 2017 with the mission to deliver transformative treatments that restore metabolic health through… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Biomea Fusion, Inc. does
In the company’s own words
Biomoda, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral, small molecule drugs to treat diabetes, obesity, and other metabolic diseases. The company was founded in 2017 with the mission to deliver transformative treatments that restore metabolic health through targeted therapies built on expertise in chemistry and metabolic biology.
The company operates with approximately 40 employees and maintains a streamlined organizational structure emphasizing capital efficiency and focused execution. Biomoda's research and development functions are supported by integrated teams in clinical development, clinical operations, clinical pharmacology, regulatory affairs, pharmacovigilance, and quality assurance. The leadership and scientific teams include members with experience from leading biotechnology and pharmaceutical companies including Gilead Sciences, Genentech, AbbVie, and Johnson & Johnson, with contributions to approved medicines such as Imbruvica, Remdesivir, and Harvoni.
Following a strategic realignment announced in 2025, Biomoda concentrates on two core drug candidate programs. Icovamenib, the company's lead clinical program, is an orally bioavailable, selective, covalent inhibitor of menin being developed in two clinical and multiple preclinical studies for type 1 and type 2 diabetes as well as obesity. BMF-650 is an investigational next-generation oral glucagon-like peptide-1 receptor agonist in development for obesity treatment. The company previously pursued oncology programs but is now focusing internal resources on metabolic disorders while exploring partnerships for its oncology assets.
Biomoda retains full worldwide development and commercialization rights to each of its product candidates. The company does not operate manufacturing facilities and relies on third-party contract manufacturers for production of its product candidates and clinical trial materials. As of December 31, 2025, Biomoda owned seven issued U.S. patents and more than 100 U.S. and international pending patent applications directed to compositions of matter, methods of treatment, and manufacturing methods for its product candidates.
The company's website is located at www.biomoda.com. Biomoda trades on the Nasdaq Global Select Market under ticker symbol BMDA.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SAN CARLOS, CA
- Fiscal year end
- December
- CIK
- 1840439
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Biomea Fusion, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Biomea Fusion, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Biomea Fusion, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Biomea Fusion, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Biomea Fusion, Inc.'s last four quarterly filings that the numbers alone won't show?”